Ribosome biogenesis is a critical process in cancer, influencing tumor progression through enhanced protein synthesis and cellular adaptation. This review explores the complex interplay between ribosome biogenesis and cancer, emphasizing the roles of key oncogenic pathways in regulating ribosome production. Dysregulated ribosome biogenesis not only supports rapid cell proliferation but also contributes to cancer stemness, epithelial-mesenchymal transition (EMT), and metastasis. Inhibiting ribosome biogenesis, particularly through RNA Polymerase I (RNA Pol I) inhibition, triggers stress responses and cell cycle arrest, suggesting that cancer cells rely on increased RNA Pol I activity. Targeting ribosome biogenesis presents a promising therapeutic strategy for cancer treatment. Ribosome biogenesis involves multiple steps, starting with the transcription of rDNA by RNA Pol I, followed by processing by RNA Pol II and III. The 47S pre-rRNA is processed into 18S, 5.8S, and 28S rRNAs, which are then assembled with ribosomal proteins. The regulation of ribosome biogenesis is influenced by oncogenic signaling pathways, including PI3K-Akt-mTORC1 and MAPKs, which promote rRNA synthesis and ribosome production. The transcription factor c-Myc also plays a key role in stimulating ribosome biogenesis, contributing to cancer progression. Tumor suppressors such as pRb and p53 inhibit rRNA synthesis, while the loss of these proteins in cancer cells leads to increased ribosome biogenesis. Aberrant rRNA processing and modifications in cancer cells are associated with decreased translation fidelity and increased translation of oncogenic mRNAs. Non-coding RNAs, such as lncRNAs, also regulate rDNA transcription, with examples like PAPAS and SLERT influencing rRNA synthesis. MicroRNAs can modulate the expression of RNA Pol I components, affecting rRNA synthesis. Additionally, variations in rDNA copy number are linked to cancer, with some cancers exhibiting increased or decreased rDNA copies, potentially influencing ribosome biogenesis and cancer progression. Ribosomopathies, characterized by reduced ribosome production, can lead to cellular hypoproliferation and increased cancer risk. Mutant ribosomal proteins and biogenesis factors can alter translation programs, contributing to a pre-oncogenic state. The interplay between ribosomal defects and cancer development highlights the importance of understanding the molecular mechanisms underlying the transition from hypoproliferation to cancer. Emerging research on onco-ribosomes and specialized translation in cancer provides new insights into potential therapeutic targets for ribosomopathies and cancer. The role of ribosome biogenesis in cancer stem cells, EMT, and metastasis underscores its significance in cancer progression, with recent studies suggesting that cancer cells may employ similar mechanisms to those in stem cells to maintain plasticity and metastatic potential.Ribosome biogenesis is a critical process in cancer, influencing tumor progression through enhanced protein synthesis and cellular adaptation. This review explores the complex interplay between ribosome biogenesis and cancer, emphasizing the roles of key oncogenic pathways in regulating ribosome production. Dysregulated ribosome biogenesis not only supports rapid cell proliferation but also contributes to cancer stemness, epithelial-mesenchymal transition (EMT), and metastasis. Inhibiting ribosome biogenesis, particularly through RNA Polymerase I (RNA Pol I) inhibition, triggers stress responses and cell cycle arrest, suggesting that cancer cells rely on increased RNA Pol I activity. Targeting ribosome biogenesis presents a promising therapeutic strategy for cancer treatment. Ribosome biogenesis involves multiple steps, starting with the transcription of rDNA by RNA Pol I, followed by processing by RNA Pol II and III. The 47S pre-rRNA is processed into 18S, 5.8S, and 28S rRNAs, which are then assembled with ribosomal proteins. The regulation of ribosome biogenesis is influenced by oncogenic signaling pathways, including PI3K-Akt-mTORC1 and MAPKs, which promote rRNA synthesis and ribosome production. The transcription factor c-Myc also plays a key role in stimulating ribosome biogenesis, contributing to cancer progression. Tumor suppressors such as pRb and p53 inhibit rRNA synthesis, while the loss of these proteins in cancer cells leads to increased ribosome biogenesis. Aberrant rRNA processing and modifications in cancer cells are associated with decreased translation fidelity and increased translation of oncogenic mRNAs. Non-coding RNAs, such as lncRNAs, also regulate rDNA transcription, with examples like PAPAS and SLERT influencing rRNA synthesis. MicroRNAs can modulate the expression of RNA Pol I components, affecting rRNA synthesis. Additionally, variations in rDNA copy number are linked to cancer, with some cancers exhibiting increased or decreased rDNA copies, potentially influencing ribosome biogenesis and cancer progression. Ribosomopathies, characterized by reduced ribosome production, can lead to cellular hypoproliferation and increased cancer risk. Mutant ribosomal proteins and biogenesis factors can alter translation programs, contributing to a pre-oncogenic state. The interplay between ribosomal defects and cancer development highlights the importance of understanding the molecular mechanisms underlying the transition from hypoproliferation to cancer. Emerging research on onco-ribosomes and specialized translation in cancer provides new insights into potential therapeutic targets for ribosomopathies and cancer. The role of ribosome biogenesis in cancer stem cells, EMT, and metastasis underscores its significance in cancer progression, with recent studies suggesting that cancer cells may employ similar mechanisms to those in stem cells to maintain plasticity and metastatic potential.